Wall Street Zen Upgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

A number of other research analysts have also recently issued reports on MIST. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on shares of Milestone Pharmaceuticals in a report on Thursday, September 11th. They set an “overweight” rating and a $4.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $4.50.

Milestone Pharmaceuticals Trading Down 1.2%

MIST stock opened at $2.37 on Friday. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $2.75. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. The business’s 50 day moving average is $2.00 and its 200-day moving average is $1.78. The firm has a market cap of $201.85 million, a P/E ratio of -2.89 and a beta of 0.54.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Propel Bio Management LLC grew its holdings in Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at approximately $6,444,000. Simplify Asset Management Inc. grew its stake in shares of Milestone Pharmaceuticals by 186.2% during the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares during the last quarter. Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $2,000,000. Finally, Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $1,333,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.